Market closed
Mineralys Therapeutics, Inc./$MLYS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Ticker
$MLYS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
51
Website
MLYS Metrics
BasicAdvanced
$904M
-
-$3.66
1.45
-
Price and volume
Market cap
$904M
Beta
1.45
52-week high
$18.38
52-week low
$8.69
Average daily volume
1.1M
Financial strength
Current ratio
14.021
Quick ratio
13.532
Management effectiveness
Return on assets (TTM)
-52.56%
Return on equity (TTM)
-82.24%
Valuation
Price to book
3.63
Price to tangible book (TTM)
3.63
Price to free cash flow (TTM)
-4.066
Growth
Earnings per share change (TTM)
84.38%
3-year earnings per share growth (CAGR)
-2.01%
MLYS News
AllArticlesVideos
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
GlobeNewsWire·7 days ago
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)
GlobeNewsWire·1 month ago
Insiders Make Huge Purchases of These 4 Biotech Stocks
24/7 Wall Street·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Mineralys Therapeutics, Inc. stock?
Mineralys Therapeutics, Inc. (MLYS) has a market cap of $904M as of April 30, 2025.
What is the P/E ratio for Mineralys Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Mineralys Therapeutics, Inc. (MLYS) stock is 0 as of April 30, 2025.
Does Mineralys Therapeutics, Inc. stock pay dividends?
No, Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders as of April 30, 2025.
When is the next Mineralys Therapeutics, Inc. dividend payment date?
Mineralys Therapeutics, Inc. (MLYS) stock does not pay dividends to its shareholders.
What is the beta indicator for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. (MLYS) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.